163759-50-0

Usage

Uses

Used in Pharmaceutical Industry:
5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine is used as a building block for the synthesis of nucleic acid analogs for the development of new drugs and therapeutic agents. Its unique structure allows for the creation of modified nucleic acids with improved properties, such as enhanced stability, target specificity, and reduced immunogenicity.
Used in Research and Development:
In the field of research and development, 5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine serves as a valuable tool for studying the structure, function, and interactions of nucleic acids. Its protected nature allows for controlled synthesis and modification, facilitating the exploration of novel nucleic acid-based technologies and applications.
Used in Diagnostics:
5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine can be employed in the development of diagnostic tools and assays, such as qPCR, FISH, and other molecular biology techniques. Its unique structure and properties can enhance the sensitivity, specificity, and reliability of these diagnostic methods.
Used in Biomaterials and Drug Delivery:
The protected uridine derivative can also be utilized in the design and fabrication of biomaterials and drug delivery systems. Its chemical and biological properties can be harnessed to create materials with controlled release, targeted delivery, and improved biocompatibility.
Used in Nanotechnology:
5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyluridine has potential applications in nanotechnology, where it can be integrated into nanostructures and devices for various purposes, such as drug delivery, imaging, and sensing. Its unique structure and properties can contribute to the development of innovative nanotechnological solutions.

Upstream product

• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 854751-16-9 chloro-bis-(2-methoxy-phenyl)-phenyl-methane 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 14983-42-7 tris(2-methoxyethyl)borate 
• 67-56-1 methanol 
• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 1463-10-1 5-Methyluridine 
• 98-07-7 Benzotrichlorid 
• 100-66-3 methoxybenzene 
• 40615-35-8 4,4'-dimethoxytrityl alcohol 
• 730979-83-6 MOE T DMT succinate 
• 163759-46-4 3-Benzyloxymethyl-1-[(2R,3R,4R,5R)-4-(2,4-dichloro-benzyloxy)-5-(2,4-dichloro-benzyloxymethyl)-3-(2-methoxy-ethoxy)-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 
• 163759-44-2 1-<2'-O-Acetyl-3',5'-bis-O-(2,4-dichlorobenzyl)-β-D-ribofuranosyl>-3-<(benzyloxy)methyl>thymin 

Downstream Products

• 182495-98-3 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 182496-01-1 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N₄-benzoyl-5-methylcytidine 
• 730979-83-6 MOE T DMT succinate 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 1345561-85-4 C₃₇H₄₆N₂O₈Si 
• 1345676-10-9 C₅₈H₆₄N₂O₁₀Si 
• 1345564-44-4 C₅₀H₅₆N₂O₉Si 
• 1221967-92-5 C₁₉H₃₄N₂O₇Si 
• 163759-94-2 MOE 5-Me-C Amidite 
• 1345720-03-7 C₂₀H₂₂N₂O₈ 
• 1345562-35-7 C₂₀H₂₄N₂O₈ 
• 1345564-47-7 C₂₉H₃₆N₂O₇Si 
• 844504-17-2 2'-O-(2-methoxy)ethyl-3'-O-(t-butyldiphenyl)silylthymidine 

Relevant academic research and scientific papers

Copper(II)nitrate catalyzed regioselective protection of primary alcohols with 4,4′-dimethoxytrityl and 2,7-dimethyl-9-phenyl xanthen-9-yl groups in nucleosides and carbohydrates

Regioselective protection of primary hydroxyl group in nucleoside and carbohydrate analogs was accomplished using dimethoxytrityl alcohol (DMTr-OH) or dimethylpixyl alcohol (DMPx-OH) in presence of copper(II)nitrate as a Lewis acid catalyst. Excellent selectivity was observed for the protection of primary hydroxyl group over secondary while glycosidic bond remain unaffected. Utility of this methodology was further exemplified via DMTr- and DMPx-protection of alipahtic acyclic and cyclic diols.

METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE CARDIOVASCULAR EVENTS USING COMPOUNDS THAT MODULATE APOLIPOPROTEIN B

Provided herein, for example, are methods generally relating to preventing, treating and/or managing a major adverse cardiovascular event in a subject with a disease or condition at risk for a major adverse cardiovascular event, e.g., familial hypercholesterolemia. Also provided herein are methods relating to administering to the patient a therapeutically effective amount of an antisense oligonucleotide having a nucleobase SEQ ID NO: 247 (e.g., mipomersen).

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of CD40 ligand expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.

Antisense modulation of PTP1B expression

Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The present invention is also directed to compositions and methods for improving insulin sensitivity in an animal or for preventing or delaying the onset of insulin resistance in an animal. Also provided are compositions and methods for treating or preventing a metabolic condition in an animal. The metabolic condition may be, e.g., diabetes or obesity.

ANTISENSE MODULATION OF LFA-3

Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a lymphocyte function associated antigen 3 (LFA-3; also known as CD58) protein are provided.

Modulation of aminopeptidase N expression

Compounds, compositions and methods are provided for modulating the expression of aminopeptidase N. The compositions comprise oligonucleotides, targeted to nucleic acid encoding aminopeptidase N. Methods of using these compounds for modulation of aminopeptidase N expression and for diagnosis and treatment of disease associated with expression of aminopeptidase N are provided.

Antisense modulation of inducible nitric oxide synthase expression

Antisense compounds, compositions and methods are provided for modulating the expression of inducible nitric oxide synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding inducible nitric oxide synthase. Methods of using these compounds for modulation of inducible nitric oxide synthase expression and for treatment of diseases associated with expression of inducible nitric oxide synthase are provided.

Antisense modulation of TFAP2C expression

Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.